EP3802785A1 - Nouvelle souche probiotique de lactobacillus brevis - Google Patents
Nouvelle souche probiotique de lactobacillus brevisInfo
- Publication number
- EP3802785A1 EP3802785A1 EP19727895.5A EP19727895A EP3802785A1 EP 3802785 A1 EP3802785 A1 EP 3802785A1 EP 19727895 A EP19727895 A EP 19727895A EP 3802785 A1 EP3802785 A1 EP 3802785A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- strain
- cncm
- cells
- lactobacillus brevis
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
Definitions
- the present invention relates to a novel probiotic strain of Lactobacillus brevis, isolated from pulque, with anti-cancer properties, as well as compositions comprising said strain.
- probiotics are “live microorganisms that, when ingested in sufficient quantity, have positive effects on health".
- Probiotic organisms used in human nutrition are generally lactic acid bacteria, mainly belonging to the genera Lactobacillus and Bifidobacterium.
- the beneficial effects of probiotic bacteria are not, however, common to all the bacteria of the same genus, or even the same species, and are found, in most cases, only in certain strains.
- the observed effects may vary from one probiotic strain to another, including within the same species.
- Pulque is a traditional Mexican alcoholic beverage derived from fermentation of the sap of various agaves, which contains a wide variety of lactic acid bacteria, particularly lactobacilli and leuconostocci (Escalante et al., Int J Food Microbiol 24: 126- 134, 2008). Recent studies suggest that some pre-Hispanic cultures in Mexico used enemas using pulque to fight diseases and disorders of the digestive system (Lemus-Fuentes, Temas de Ciencia y Tecnologia 102: 143-150, 2006).
- lactobacilli including strains of Lactobacillus san franciscensis, Lactobacillus plantarum and Lactobacillus composti
- lactobacilli isolated from pulque have anti-inflammatory properties potentially beneficial for the treatment of inflammatory bowel diseases (Torres Maravilla et al., Appl Microbiol Biotechnol 100: 385-396, 2015).
- the inventors have succeeded in isolating a new strain of Lactobacillus brevis possessing anticancer properties. Surprisingly and unexpectedly, the inventors have thus shown that said strain is capable of reducing the proliferation of lines tumor cells and modify the expression of certain pro-apoptotic genes or genes involved in tumor development.
- the present invention thus relates to this strain of Lactobacillus brevis, deposited according to the Budapest Treaty, with the CNCM (National Collection of Cultures of Microorganisms, 25 rue du Dondel Roux, 75724 Paris Cedex 15) on May 30, 2018 under the number 1-5321.
- the CNCM 1-5321 strain was identified as belonging to the L. brevis species using a CHL API 50 test and by sequencing G 16S RNA.
- the anticancer properties of the CNCM 1-5321 strain are independent of its viability state. Therefore, the present invention encompasses the CNCM 1-5321 strain regardless of its viability state, not only in living form, but also in dead form, in inactivated form or in the form of a bacterial lysate.
- the CNCM 1-5321 strain may be in the exponential or stationary growth phase, preferably in the exponential phase.
- a bacterium is considered alive if it is able to multiply. Conversely, a bacterium is considered dead or inactivated when it has lost its ability to multiply.
- Techniques for inactivating bacteria are well known to those skilled in the art.
- the CNCM 1-5321 strain can be inactivated by exposure to ultraviolet radiation or by heating.
- the CNCM 1-5321 strain can be inactivated according to the method described in Neyzi et al., In Vitro Cell. Dev. Biol.-Animal 53: 12-19, 2017. Briefly, the bacterial culture is centrifuged for 10 min, then the cell pellet is resuspended in PBS and exposed to UV radiation for 15 minutes to inactivate the bacterium. To ensure that the bacteria is no longer able to multiply, a control culture is performed in SRM after UV treatment.
- the present invention also encompasses strains that can be obtained by mutagenesis or by genetic transformation of the CNCM 1-5321 strain.
- the methods for mutating or transforming the CNCM 1-5321 strain are well known to those skilled in the art and correspond to the methods used routinely to modify the genome of lactic acid bacteria, in particular bacteria belonging to the Lactobacillus brevis species. Such methods include, but are not limited to, random mutagenesis (e.g., using UV radiation or a mutagenic chemical agent), site-directed mutagenesis, or homologous recombination.
- these strains retain at least the anti-cancer properties of the CNCM 1-5321 strain.
- These may be strains in which one or more of the genes of the CNCM 1-5321 strain have been mutated, for example to modify certain metabolic properties (eg the ability of this strain to resist acidity, resist intestinal transit, metabolize certain sugars, ). It may also be strains resulting from the genetic transformation of the CNCM 1-5321 strain by one or more gene (s) of interest, allowing, for example, to confer on said strain additional physiological characteristics or to express proteins. of interest that it is desired to administer via said strain.
- the present invention also relates to a cell fraction obtainable from the CNCM 1-5321 strain.
- it may be a bacterial wall preparation obtained from a culture of said strain. More particularly, it may be a preparation of peptidoglycan obtained from said strain. They may also be culture supernatants or fractions of these supernatants.
- Cell fractions can be prepared according to methods known to those skilled in the art. In a nonlimiting manner, these methods generally comprise a step of lysis of the bacteria obtained after cultivation and a step of separation of the fractions containing the membranes of said bacteria from the total lysate obtained after the lysis step, in particular by centrifugation or filtration.
- cell fractions can be prepared by sonification according to the method described in Tiptiri-Kourpeti et al., PLOS one 11 (2): e0l47960, 2016.
- the present invention relates to L. brevis strain CNCM 1-5321 or a cell fraction of said strain for use as a medicament.
- the CNCM 1-5321 strain or a cell fraction of the CNCM 1-5321 strain is ingested orally or administered mucosally, in particular intranasally.
- L. brevis CNCM 1-5321 strain or a cell fraction thereof is administered daily to the patient.
- L. brevis CNCM 1-5321 strain or a cell fraction thereof is administered at least once a day.
- L. brevis CNCM 1-5321 strain or a cell fraction thereof is administered at least once a week.
- the present invention relates to the L. brevis CNCM 1-5321 strain or a cell fraction of said strain for use in the prevention and / or treatment of cancer, particularly bowel cancer, more particularly colorectal cancer, but also other types of carcinoma such as breast cancer, lung cancer, liver cancer, etc.
- the strain of the invention inhibits the proliferation of tumor cell lines, in particular human lines HT29, HTC116 and Caco2 derived from colorectal adenocarcinoma cells.
- the present invention relates to L. brevis strain CNCM I-5321 or a cell fraction of said strain for its use as defined above, wherein said strain inhibits the proliferation of cancer cells.
- the present invention relates to the L. brevis strain CNCM I-5321 or a cell fraction of said strain for its use as defined above, wherein said strain or the cell fraction of said strain increases the expression of at least one pro-apoptotic gene in said cancer cells.
- said pro-apototic gene is selected from the group of genes comprising CASP8, CASP9, BCL2, BAX and BCI.-XI.
- the present invention relates to L. brevis strain CNCM I-5321 or a cell fraction of said strain for its use as defined above, in which said strain or the cell fraction of said strain decreases the expression of at least one gene involved in the development of a tumor.
- said gene involved in the development of a tumor is selected from the group of genes comprising erbB2, erbB3 and PKM2.
- the present invention relates to a method of treatment in a subject in need comprising administering L. brevis strain CNCM 1-5321 or a cell fraction of said strain to said subject.
- the present invention also relates to a method of treating cancer in a subject in need comprising administering L. brevis strain CNCM 1-5321 or a cell fraction of said strain to said subject.
- the present invention relates to the use of L. brevis strain CNCM 1-5321 or a cell fraction of said strain for the preparation of a medicament.
- the present invention also relates to the use of L. brevis CNCM 1-5321 strain or a cell fraction of said strain for the preparation of a medicament for the treatment of cancer.
- the present invention provides a composition comprising L. brevis strain CNCM 1-5321 or a cell fraction thereof.
- a composition according to the invention can be liquid or solid and be in various forms, such as for example a capsule, a tablet, a tablet, a pill, a suppository, a powder bag, a bottle of liquid, a liquid ampoule, etc ...
- a composition according to the invention may contain a coating, in particular a gastro-resistant coating or a coating allowing enteric release of the CNCM 1-5321 strain.
- the present invention relates to a composition as defined above, said composition being a pharmaceutical product or a food product, in particular a food supplement.
- the term "food supplement” refers to a food product providing a complement of nutrients or substances having a nutritional or physiological effect (such as vitamins, minerals, fatty acids or amino acids) missing or in quantities insufficient in the normal diet of an individual.
- the present invention relates to a composition as defined above, said composition also comprising at least one element selected from the group consisting of vitamins, minerals, fatty acids and amino acids.
- the vitamins used in the manufacture of food supplements are generally vitamins A, D, E, K, B1, B2, B6, B12 and C, Niacin, Pantothenic acid, folic acid and Biotin.
- the minerals used in the manufacture of food supplements are generally chosen from calcium, magnesium, iron, copper, iodine, zinc, manganese, sodium, potassium, selenium, Chromium, Molybdenum, Fluoride, Chloride, Phosphorus.
- the present invention relates to a composition as defined above, said composition also comprising at least one excipient.
- the present invention relates to a composition as defined above, said composition also comprising at least one flavoring.
- the present invention relates to a composition as defined above, said composition being a beverage.
- strains When said strain is present in the form of living bacteria, these are preferably present in an amount of at least 10 5 cfu per gram of product, preferably least 10 6 CFU per gram, more preferably at least 10 7 CFU per gram, and even more preferably at least 10 cfu per gram.
- the present invention relates to a composition as defined above, in which the CNCM 1-5321 strain is in association with another probiotic organism, preferably a lactic acid bacterium.
- FIG. 1 Antiproliferative effect of the CNCM 1-5321 strain on tumor cell lines.
- the HT29, HTC116 and Caco2 cells are incubated in the presence of PBS (negative control), 5-FU (5 Fluorouracil) (positive control), strain CNCM 1-5321, L. casei strain BL23 and the strain. L. casei ATCC334. * indicates a significant difference from the negative control (P ⁇ 0.05).
- FIG. 1 Antiproliferative effect of UV inactivated strain CNCM 1-5321 on tumor cell lines.
- the HT29, HTC116 and Caco2 cells are incubated in the presence of PBS (negative control), 5-FU (5 Fluorouracil) (positive control), the CNCM 1-5321 strain, the culture supernatant of the CNCM 1-5321 strain ( MRS medium) and UV inactivated strain CNCM I-5321. * indicates a significant difference from the negative control (P ⁇ 0.05).
- FIG. 3 Anti-proliferative effect of the cell pellet of the CNCM 1-5321 strain after sonication on the tumor cell lines.
- the HT29, HTC116 and Caco2 cells are incubated in the presence of PBS (negative control), 5-FU (5 Fluorouracil) (positive control), the CNCM 1-5321 strain and the cell pellet of the CNCM 1-5321 strain after sonication. . * indicates a significant difference from the negative control (P ⁇ 0.05).
- FIG. 4 Pro-apoptotic effects of the CNCM 1-5321 strain on tumor cell lines.
- the HT29 and HTC116 cells are incubated 24h with the CNCM 1-5321 strain.
- the viability of the cell lines was determined by staining with annexin V-FITC and propidium iodide (PI) followed by flow cytometric analysis.
- PI propidium iodide
- FIG. 6 Specificity of the antiproliferative effect of the CNCM 1-5321 strain on tumor lines.
- the colon cancer cells (HT29 line) are incubated in the presence of PBS (negative control), 5-FU (positive control) and CNCM 1-5321 strain.
- Non-cancerous colon cells (FHC line) are incubated in the presence of PBS (negative control), 5-FU (positive control) and CNCM 1-5321 strain. * indicates a significant difference from the negative control (P ⁇ 0.05).
- Lactobacilli were grown in Man-Rogosa-Sharpe (MRS) medium (Difco Laboratories) for one day at 37 ° C.
- MRS Man-Rogosa-Sharpe
- the pellet was washed twice with PBS and a cell extract was obtained by sonication (10 cycles between 40 and 60 watts amplitude).
- the soluble and insoluble components were separated by centrifugation, the protein content was quantified by Bradford.
- the supernatant was obtained by centrifugation after one night of culture, followed by filtration sterilization (0.45 ⁇ m).
- the bacteria were killed by exposure to UV radiation for 15 min. Inactivation was confirmed by incubation on Petri dishes.
- DMEM glucose-rich Dulbecco's Modified Eagle Medium
- FBS fetal bovine serum
- 2mM L-glutamine 50 mg / ml penicillin and 50 mg / ml streptomycin in a humidified atmosphere containing 5% C0 2 .
- the non-cancerous FHC cell line was cultured in DMEM / F12 medium supplemented with 10% (vol / vol) FBS, 2mM L-glutamine, 50mg / ml penicillin and 50mg / ml streptomycin, 0.005 mg / ml insulin, 0.005 mg / ml transferrin, 0.00067 mg / ml hydrocortisone, 20ng / ml human epidermal growth factor (EGF) in a humidified atmosphere containing 5% C0 2 .
- DMEM / F12 medium supplemented with 10% (vol / vol) FBS, 2mM L-glutamine, 50mg / ml penicillin and 50mg / ml streptomycin, 0.005 mg / ml insulin, 0.005 mg / ml transferrin, 0.00067 mg / ml hydrocortisone, 20ng / ml human epidermal growth factor (EGF) in
- the cells were seeded on 96-well microplates at a rate of 2 ⁇ 10 4 cells per well.
- the co-culture with a bacterium (2 ⁇ 10 6 cells) was then carried out for 24 and 48 h.
- the cells were fixed in 5% trichloroacetic acid (TCA) for 1 hour at 4 ° C and washed four times in distilled water.
- TCA 5% trichloroacetic acid
- the microplates were stained with 100 ⁇ l / well of 0.057% (w / v) sulforhodamine (SRB) / distilled water, washed 4 times in 0.1% acetic acid and re dehydrated at room temperature.
- the stained cells were lysed in 10 mM Tris buffer and the optical density (OD) was measured at 510 nm.
- HT-29 cells were seeded at 1 x 10 6 cells / ml and allowed to fix overnight at 37 ° C in a CO 2 incubator.
- the culture with a bacterium (1 x 10 8 cells) was carried out for 24 h.
- the cells were harvested (tripsination) and washed twice with cold PBS, and resuspended in IX binding buffer at a concentration of 1 x 10 6 cells / ml.
- the cells were incubated with 5 ⁇ l of Annexin V-FITC and 5 ⁇ l PI for 15 min at room temperature (25 ° C) under dark conditions. 400 ⁇ l of IX binding buffer was added to each tube and the cells were analyzed by flow cytometry.
- the controls used are (i) untreated cells, and cells stained with (ii) Annexin V-FITC only, (iii) GIR only, and (iv) both Annexin V-FITC. and PI.
- RNA was extracted using the Qiagen RNeasy Mini Kit. The quality and concentration of the RNA were examined by ethidium bromide agarose gel electrophoresis and spectrophotometric analysis.
- the cDNA template was synthesized from 1 ⁇ g of RNA with the High-Capacity Reverse Transcription Kit cDNA Reverse Transcription Kit (Applied Biosystems).
- RT-qPCR The reaction of RT-qPCR was carried out in a reaction volume of 25 ml (Takyon TM Rox SYBR® MasterMix dTTP blue) with the following primers: B-actin, Caspas8, Caspas9, ErbB2, ErbB3, BCL2, BCL-XL in the first heat cycle qPCR. Expression values were quantified and normalized by the ACt method, using the geometric mean Ct of b-actin as the endogenous reference gene.
- CNCM 1-5321 A test for the antiproliferative activity of the CNCM 1-5321 strain was performed on various colon cancer cell lines, HT-29 (human colon adenocarcinoma, type II), HTC116 (human colorectal cancer), and Caco-2 (colorectal adenocarcinoma).
- the CNCM 1-5321 strain is able to stop the cellular proliferation of epithelial lineages human intestinal tract at a level comparable to that of 5-fluorouracil (5-FU), an anticancer drug used here as a positive control ( Figure 1).
- 5-FU 5-fluorouracil
- the CNCM 1-5321 strain is also capable of increasing annexin V + / PI + levels (late apoptotic cells, FIG. 4) by 25% and inducing apoptotic cell death by activating and suppressing the expression of anti-apoptotic genes ErbB2, ErbB3 (via Casp8), two genes initiating apoptosis mediated by TNF- ⁇ , and modulating the expression of BAX and PKM2 genes involved in cellular metabolism (Figure 5).
- CNCM 1-5321 strain To determine whether the anti-proliferative effect of the CNCM 1-5321 strain is specific to the tumor lines, a test of the antiproliferative activity was carried out on the HT29 tumor line (human colon adenocarcinoma, type II) and on the line non-cancerous FHC (fetal human colon cells).
- the CNCM 1-5321 strain inhibits cell proliferation of the tumor line, but has no significant effect on non-cancer cell growth ( Figure 6).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1854912A FR3082207B1 (fr) | 2018-06-06 | 2018-06-06 | Nouvelle souche probiotique de lactobacillus brevis |
PCT/EP2019/064600 WO2019234076A1 (fr) | 2018-06-06 | 2019-06-05 | Nouvelle souche probiotique de lactobacillus brevis |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3802785A1 true EP3802785A1 (fr) | 2021-04-14 |
Family
ID=62952143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19727895.5A Pending EP3802785A1 (fr) | 2018-06-06 | 2019-06-05 | Nouvelle souche probiotique de lactobacillus brevis |
Country Status (5)
Country | Link |
---|---|
US (1) | US11471498B2 (fr) |
EP (1) | EP3802785A1 (fr) |
CA (1) | CA3102179A1 (fr) |
FR (1) | FR3082207B1 (fr) |
WO (1) | WO2019234076A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115806901B (zh) * | 2022-09-01 | 2023-08-04 | 昆明医科大学 | 一株短乳杆菌及其抗宫颈癌应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0755908B2 (ja) * | 1992-11-24 | 1995-06-14 | 財団法人京都パストゥール研究所 | 免疫機能助長剤 |
IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
-
2018
- 2018-06-06 FR FR1854912A patent/FR3082207B1/fr active Active
-
2019
- 2019-06-05 CA CA3102179A patent/CA3102179A1/fr active Pending
- 2019-06-05 US US15/734,375 patent/US11471498B2/en active Active
- 2019-06-05 WO PCT/EP2019/064600 patent/WO2019234076A1/fr unknown
- 2019-06-05 EP EP19727895.5A patent/EP3802785A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019234076A1 (fr) | 2019-12-12 |
CA3102179A1 (fr) | 2019-12-12 |
FR3082207B1 (fr) | 2022-03-25 |
US20210268044A1 (en) | 2021-09-02 |
US11471498B2 (en) | 2022-10-18 |
FR3082207A1 (fr) | 2019-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4282489A2 (fr) | Traitement d'une infection par clostridium difficile | |
EP1931363B1 (fr) | Traitement des maladies intestinales inflammatoires par l'utilisation, en tant qu'effecteurs thérapeutiques, de bactéries probiotiques et de céréales fermentées | |
JP4163276B2 (ja) | 機能性組成物 | |
Song et al. | Probiotic characteristics of Lactobacillus brevis B13-2 isolated from kimchi and investigation of antioxidant and immune-modulating abilities of its heat-killed cells | |
TWI241912B (en) | Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol | |
KR102240196B1 (ko) | 신규한 락토바실러스 파라카세이 균주 | |
EP1791946A1 (fr) | Lactobacillus plantarum avec activite reductrice de corps gras et aliments contenant cette souche | |
KR20150143803A (ko) | 락토바실러스속 균 함유 조성물 | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
Seo et al. | Development of Anti-inflammatory Probiotic Limosilactobacillus reuteri EFEL6901 as Kimchi Starter: in vitro and In vivo Evidence | |
EP2537523B1 (fr) | Agent prophylactique/d'amélioration pour des maladies, agent d'amélioration de l'endurance et agent antifatigue, et agent pharmaceutique, aliment et boisson comprenant chacun l'un quelconque de ces agents | |
KR102368628B1 (ko) | Iv형 알레르기용 조성물 | |
WO2019234076A1 (fr) | Nouvelle souche probiotique de lactobacillus brevis | |
EP3511406A1 (fr) | Faecalibacterium longum et application associée | |
WO2017188157A1 (fr) | Agent pour réguler le rapport de composition de la flore bactérienne intestinale, médicament, aliment, boisson et procédé de régulation du rapport de composition de la flore bactérienne intestinale | |
KR102323673B1 (ko) | HtrA 샤페론 프로바이오틱스의 제조방법 및 이를 통해 제조된 장 마이크로바이옴 조절 효능이 있는 염증성 장질환 치료용 조성물 | |
KR102368626B1 (ko) | I형 알레르기용 조성물 | |
JP7195714B2 (ja) | 炎症性腸疾患用組成物 | |
AU2013201442A1 (en) | Treatment of IBD and IBS using both probiotic bacteria and fermented cereal as treatment effectors | |
WO2022191183A1 (fr) | Composition et agent d'amélioration présentant une action d'inhibition de l'inflammation | |
Zykovа et al. | Development of the biotechnology for obtaining a dietary supplement from the seleniumcontaining probiotic cultures lactobacillus acidophilus 412/307 and bifidobacterium bifidum 1 | |
RU2575625C1 (ru) | ШТАММЫ Lactobacillus plantarum И Lactobacillus brevis, СИНТЕЗИРУЮЩИЕ ГАММА-АМИНОМАСЛЯНУЮ КИСЛОТУ | |
Paturi | Probiotic characteristics of Lactobacillus acidophilus and Lactobacillus paracasei and their effects on immune response and gene expression in mice | |
Fossi et al. | Screening and molecular characterization of cholesterol-lowering lactic acid bacteria isolated from African oil palm wine (Elaeis guineensis) and corn beer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20201218 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |